Barchiesi F, Schimizzi AM, Caselli F et al (2001) Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48(6):769–773. https://doi.org/10.1093/jac/48.6.769

Article  CAS  PubMed  Google Scholar 

Cacciapuoti A, Loebenberg D, Corcoran E et al (2000) In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 44(8):2017–2022. https://doi.org/10.1128/AAC.44.8.2017-2022.2000

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46(2):229–234. https://doi.org/10.1093/jac/46.2.229

Article  CAS  PubMed  Google Scholar 

Pfaller MA, Messer SA, Hollis RJ, Jones RN (2001) In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 45(10):2862–2864. https://doi.org/10.1128/AAC.45.10.2862-2864.2001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfaller MA, Messer SA, Hollis RJ, Jones RN (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 46(4):1032–1037. https://doi.org/10.1128/AAC.46.4.1032-1037.2002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 356(4):348–359. https://doi.org/10.1056/NEJMoa061094

Article  CAS  PubMed  Google Scholar 

Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347. https://doi.org/10.1056/NEJMoa061098

Article  CAS  PubMed  Google Scholar 

Girmenia C, Frustaci AM, Gentile G et al (2012) Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 97(4):560–567. https://doi.org/10.3324/haematol.2011.053058

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lerolle N, Raffoux E, Socie G et al (2014) Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 20(11):O952-959. https://doi.org/10.1111/1469-0691.12688

Article  CAS  Google Scholar 

Jang SH, Colangelo PM, Gobburu JVS (2010) Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 88(1):115–119. https://doi.org/10.1038/clpt.2010.64

Article  CAS  PubMed  Google Scholar 

Lipp H-P (2010) Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol 70(4):471–480. https://doi.org/10.1111/j.1365-2125.2010.03680.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57(2):218–222. https://doi.org/10.1046/j.1365-2125.2003.01977.x

Article  PubMed  PubMed Central  Google Scholar 

Gubbins PO, Krishna G, Sansone-Parsons A et al (2006) Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 50(6):1993–1999. https://doi.org/10.1128/AAC.00157-06

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walravens J, Brouwers J, Spriet I et al (2011) Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet 50(11):725–734. https://doi.org/10.2165/11592630-000000000-00000

Article  CAS  PubMed  Google Scholar 

Krishna G, Moton A, Ma L, Medlock MM, McLeod J (2009) Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53(3):958–966. https://doi.org/10.1128/AAC.01034-08

Article  CAS  PubMed  Google Scholar 

Krishna G, Ma L, Vickery D et al (2009) Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 53(11):4749–4752. https://doi.org/10.1128/AAC.00889-09

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kohl V, Müller C, Cornely OA et al (2010) Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 54(1):207–212. https://doi.org/10.1128/AAC.01027-09

Article  CAS  PubMed  Google Scholar 

Krishna G, AbuTarif M, Xuan F et al (2008) Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28(10):1223–1232. https://doi.org/10.1592/phco.28.10.1223

Article  CAS  PubMed  Google Scholar 

Lebeaux D, Lanternier F, Elie C et al (2009) Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 53(12):5224–5229. https://doi.org/10.1128/AAC.00939-09

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H (2007) Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27(12):1627–1636. https://doi.org/10.1592/phco.27.12.1627

Article  CAS  PubMed  Google Scholar 

Sengar M, Dsouza S, Deshpande R et al (2016) Therapeutic drug monitoring of posaconazole in adult acute myeloid leukemia (Aml) patients receiving posaconazole prophylaxis during induction: experience from a center with high invasive fungal infection (IFI)Burden. Blood 128(22):4005–4005. https://doi.org/10.1182/blood.V128.22.4005.4005

Article  Google Scholar 

Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H (2010) Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 49(6):379–396. https://doi.org/10.2165/11319340-000000000-00000

Article  CAS  PubMed  Google Scholar 

Cornely OA, Ullmann AJ (2011) Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 89(3):351–352. https://doi.org/10.1038/clpt.2010.261

Article  CAS  PubMed  Google Scholar 

De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis Off Publ Infect Dis Soc Am 46(12):1813–1821. https://doi.org/10.1086/588660

Article  Google Scholar 

Ezzet F, Wexler D, Courtney R et al (2005) Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 44(2):211–220. https://doi.org/10.2165/00003088-200544020-00006

Article  CAS  PubMed  Google Scholar 

Cendejas-Bueno E, Forastiero A, Rodriguez-Tudela JL, Cuenca-Estrella M, Gomez-Lopez A (2012) HPLC/UV or bioassay: two valid methods for posaconazole quantification in human serum samples. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 18(12):1229–1235. https://doi.org/10.1111/j.1469-0691.2011.03732.x

Article  CAS  Google Scholar 

Dekkers BGJ, Bakker M, van der Elst KCM et al (2016) Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep 10:51–61. https://doi.org/10.1007/s12281-016-0255-4

Article  PubMed  PubMed Central  Google Scholar 

Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW (2014) Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69(5):1162–1176. https://doi.org/10.1093/jac/dkt508

Article  CAS  PubMed  Google Scholar 

Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245. https://doi.org/10.1038/clpt.1981.154

Article  CAS  PubMed  Google Scholar 

Bryant AM, Slain D, Cumpston A, Craig M (2011) A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 37(3):266–269. https://doi.org/10.1016/j.ijantimicag.2010.11.021

Article  CAS  PubMed  Google Scholar 

Hummert SE, Green MR (2015) Therapeutic drug monitoring and dose adjustment of posaconazole oral suspension in adults with acute myeloid leukemia. Ther Drug Monit 37(4):508–511. https://doi.org/10.1097/FTD.0000000000000175

Article  CAS  PubMed